Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
biotech IPO
Biotech
Hemab CEO seeks ‘flavor of a multi-product coagulation company’
With the post-IPO quiet period having come to an end, CEO Benny Sørensen, M.D., Ph.D., was free to sit down with Fierce to map out Hemab’s future.
Will Maddox
Aug 13, 2026 9:00am
BlossomHill, Latigo outshine IPO expectations
Aug 7, 2026 11:10am
Braveheart charges to $382.5M IPO to fund Hengrui cardio drug
Aug 6, 2026 8:27am
Attovia's CEO aims to scratch itch opportunity with $289M IPO
Aug 5, 2026 7:00am
Latigo laces up for $247M IPO to fund rival to Vertex’s Journavx
Aug 4, 2026 7:55am
BlossomHill eyes $112M IPO harvest to fund Tagrisso challenger
Aug 3, 2026 9:18am
